OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Communications is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
	602
	416
Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor	375
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”	335
Issue Information	334
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation	288
Issue Information	259
Issue Information	231
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma	187
Dysregulated Proline Metabolism Exacerbates Hepatocellular Carcinoma Metastasis via EPRS1-Mediated mRNA Translation	180
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort	172
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study	170
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update	162
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives	159
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity	157
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy	148
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study	143
Current status and perspectives of esophageal cancer: a comprehensive review	142
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial	131
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer	122
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions	122
Issue Information	114
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer	105
	101
Issue Information	101

	87
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study	83
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward	77
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h	77
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence	76
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity	74
N ⁶ ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas	73
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of	73
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer	72
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer	69
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica	69
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses	67
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism	66
Cover Image, Volume 45, Issue 6	65
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials	65
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma	63
FOXO1 or not FOXO1: that is the question	62
Issue Information	59
Antitumoral effects of cannabis in Notch1 ‐mutated T‐cell acute lymphoblastic leukemia	58
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expression	58
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML	57
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma	56
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades	53
Ubiquitination in cancer: mechanisms and therapeutic opportunities	53
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene	52
Harnessing chimeric antigen receptor macrophages against solid tumors	52
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation	50
Correction to “Circulating tumor cells share RNA modules with early embryo trophectoderm and with metastatic cancer”	49
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial	49
Low household income and income volatility increase risk of lung cancer: A nationwide retrospective cohort study	48
Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences	48
Issue Information	47
Enhanced selection of people for lung cancer screening using AHRR (cg05575921) or F2RL3 (cg03636183) methy	46
An HGF‐dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis	44
Breast cancer: an up‐to‐date review and future perspectives	44
m ⁶ A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma	44
Development of antibody‐drug conjugates in cancer: Overview and prospects	43
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists	42
Inhibition of mTOR attenuates the initiation and progression of BRCA1 ‐associated mammary tumors	41
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization	41
Vebreltinib for Previously Treated Astrocytoma, IDH -Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with	41
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract	40
Neuroinflammation drives apathy in cancer cachexia	40
Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy	39
circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer	39
Long‐term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants	39
Issue Information	38
	38
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA	38
Single‐cell and bulk transcriptomics identifies a tumor‐specific CD36 ⁺ cancer‐associated fibroblast subpopulation in colorectal cancer	37

Issue Information	37
Cover Image, Volume 44, Issue 4	37
Knowing nodal Rouviére: the power of human intelligence in toxicity reduction	37
Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study	36
Issue Information	36
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium	34
Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China	34
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms	34
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins	33
Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis	33
NSUN2 Promotes Cancer Immune Evasion via its Moonlighting Function Acting on Metabolic Reprogramming	33
Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy	32
Breaking barriers: Smart vaccine platforms for cancer immunomodulation	32
Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence	32
Tumor microenvironment signaling and therapeutics in cancer progression	31
	30
The Ly6g ^high Neutrophil Subset Dictates Breast Cancer Lung Metastasis via CD8 ⁺ T Cell Death	30
Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti‐PD‐1 therapy	29
TOPK Suppresses the CD8 ⁺ T Cell Antitumor Immunity via Modulation of IRF5 Expression	29
A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment	28
Cover Image, Volume 43, Issue 6	27
Issue Information	27
Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study	27
Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy	27
Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL3	26
Single‐cell‐eQTL mapping in circulating immune cells reveals genetic regulation of response‐associated networks in lung cancer immunotherapy	25
Targeting ferroptosis resistance resensitizes metastatic HR ⁺ HER2 ⁻ breast cancer cells to palboc	25
Leptin‐mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer	24
The regulatory roles and clinical significance of glycolysis in tumor	24
Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China	23
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy	23
HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism	23
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK- Positive Non-Small Cell Lung Cancer	23
	23
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors	23
In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery	22
Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis	22
Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes in the Mouse Endometrium Recapitulates High-Risk Endometrial Carcinoma	22
Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors	22
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients	21
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinica	21
Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation	21
Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor	20
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors	20
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma	20
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer	20
Transient and DNA‐free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis	20
The SARS‐CoV‐2 spike protein induces lung cancer migration and invasion in a TLR2‐dependent manner	20
Macrophages drive ferroptosis resistance after radiotherapy	19
Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types	19
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial	19
NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma	18
TGFBR1 *6A and Risk for Colorectal Cancer	18
Diagnostic value of genetic mutation analysis and mutation profiling of cell‐free DNA in intraocular fluid for vitreoretinal lymphoma	18
TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy	18
Excess Weight May Account for More Than 10% of All Cancers: The Underestimated Impact of the Obesity Epidemic	18